BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells

Rhea-AI Summary

BioAdaptives (OTC: BDPT) announced upcoming commercial availability of XcellaraHeart™, a cardiovascular wellness supplement combining the Xcellara™ stem/progenitor cell mobilization base with Tanshinone IIA, a Danshen-derived compound. The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks.

According to BioAdaptives, XcellaraHeart™ targets two areas: stem/progenitor cell “supply” and cardiovascular repair-related signaling support via pathways studied around the SDF-1α/CXCR4 chemokine axis. A scientific evidence dossier and ordering will be available online, with orders opening August 1, 2026 and first deliveries expected in early August.

News Market Reaction – BDPT

+233.33%

+233.33% Session close to close

In the Jul 15 session, BDPT gained 233.33%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology

LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support.

XcellaraHeart™ is built on the Company’s Xcellara™ base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. The Company believes this clinical result provides a strong foundation for XcellaraHeart’s supply-side strategy: maintaining a healthy circulating pool of stem/progenitor-type cells.

The second component of the formula is Tanshinone IIA, a natural bioactive compound derived from Danshen root (Salvia miltiorrhiza). Tanshinone IIA has been studied in peer-reviewed cardiovascular research for its effects on the SDF-1α/CXCR4 chemokine axis, a signaling pathway linked to cellular trafficking, cardiovascular repair biology, and tissue-specific signaling.

XcellaraHeart™ was developed around a two-part cardiovascular-wellness strategy:

1. Supply: The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks.
2. Signaling: Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair-response biology.

“Traditional cardiovascular supplements often focus on circulation, antioxidant status, or vascular elasticity,” said James Keener, CEO of BioAdaptives® Inc. “XcellaraHeart™ was developed to take a broader approach, combining the Xcellara™ stem/progenitor-cell mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its role in the SDF-1α/CXCR4 signaling pathways linked to cellular trafficking and cardiovascular wellness.”

BioAdaptives® developed XcellaraHeart™ based on the hypothesis that increasing circulating stem/progenitor-type cells may be more meaningful when paired with nutrients that support tissue-specific signaling pathways. The Company believes Tanshinone IIA is a particularly compelling candidate for cardiovascular wellness because of its long research history and published evidence on cardiovascular signaling pathways.

The complete scientific evidence dossier for the formulation is available at products.xcellara.com/science. The dossier will separate findings from BioAdaptives’ human clinical research on the Xcellara™ base, published research on Tanshinone IIA, and the Company’s product-development rationale for combining the two.

XcellaraHeart™ will be available for order at products.xcellara.com/xcellaraheart, starting Aug. 1, 2026, with first deliveries expected in early August. General information on new products awaiting rollout is available at products.xcellara.com.

About BioAdaptives® Inc.

BioAdaptives® Inc. is the developer of the Xcellara™ line of stem cell mobilization and tissue-homing supplements. The Company’s flagship Xcellara™ base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. For more information, visit products.xcellara.com.

The complete scientific evidence dossier for the XcellaraHeart™ formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara™ base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two.

Availability

XcellaraHeart™ will be available for order at products.xcellara.com/xcellaraheart starting August 1, 2026, with first deliveries expected soon after. General information on new products awaiting rollout is available at products.xcellara.com.

Regulatory Disclaimer

These statements have not been evaluated by the Food and Drug Administration. XcellaraHeart™ is not intended to diagnose, treat, cure, or prevent any disease. Xcellara™ is a trademark of BioAdaptives^® Inc.

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for humans and animals. Its formulations are grounded in published research on nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, intended benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.

INVESTOR & MEDIA CONTACT

Emily Harrison
Investor Relations, BioAdaptives, Inc.
702-703-1233 | info@bioadaptives.com | www.bioadaptives.com
X – @BioAdaptivesInc

James Keener, CEO
BioAdaptives^® Inc.
Las Vegas, NV
702-334-4424
Ewells@bioadaptives.com
products.xcellara.com

FAQ

What is BioAdaptives (OTC: BDPT) XcellaraHeart™ and its main purpose?

XcellaraHeart™ is a cardiovascular wellness supplement that combines BioAdaptives’ Xcellara™ stem/progenitor cell mobilization base with Tanshinone IIA. According to BioAdaptives, it is designed around stem/progenitor cell “supply” and cardiovascular repair-related signaling support via the SDF-1α/CXCR4 chemokine pathway.

What human-clinical data supports BioAdaptives (BDPT) Xcellara™ base used in XcellaraHeart™?

According to BioAdaptives, the Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial. That study documented an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks of use, providing the foundation for XcellaraHeart’s supply-side strategy.

How does Tanshinone IIA contribute to BioAdaptives (BDPT) XcellaraHeart™ formula?

Tanshinone IIA is a natural compound from Danshen root included as XcellaraHeart’s signaling-support component. According to BioAdaptives, it has been studied in peer-reviewed cardiovascular research for effects on the SDF-1α/CXCR4 chemokine axis, linked to cellular trafficking and cardiovascular repair biology.

When will BioAdaptives (BDPT) XcellaraHeart™ be available to order?

According to BioAdaptives, XcellaraHeart™ will be available for order starting August 1, 2026 at products.xcellara.com/xcellaraheart. The company expects first deliveries in early August, with additional information on upcoming products available at products.xcellara.com.

How does XcellaraHeart™ differ from traditional cardiovascular supplements from an investor’s perspective (BDPT)?

BioAdaptives states that traditional cardiovascular supplements often focus on circulation, antioxidant status, or vascular elasticity. XcellaraHeart™ instead combines a clinically supported stem/progenitor-cell mobilization base with Tanshinone IIA, studied for SDF-1α/CXCR4 signaling, targeting both cellular supply and cardiovascular repair-related signaling support.

Where can investors review the scientific evidence for BioAdaptives (BDPT) XcellaraHeart™ formulation?

According to BioAdaptives, a complete scientific evidence dossier is available at products.xcellara.com/science. The dossier separates BioAdaptives’ human clinical research on the Xcellara™ base, published research on Tanshinone IIA, and the company’s rationale for combining these components in the XcellaraHeart™ formulation.